Bhubaneswar, Oct 27: Latest advancements in the field of molecular hematology, which has a direct impact on cancer diagnosis, prognosis and treatment, were discussed at a workshop held at the Institute of Medical Sciences and SUM Hospital here.
The Continued Medical Education (CME) program on the subject ‘Molecular Hematology—The Future We Are Living In’, conducted on hybrid mode on Wednesday, attracted delegates from all over the state and from outside as well.
Experts belonging to the field spoke about advanced molecular tests involving polymerase chain reaction (PCR), Fluorescence in situ hybridization (FISH), cytogenetics, sanger sequencing and Next Generation Sequencing (NGS) saying these procedures had become the backbone of patient care in hematology, oncology and other disciplines of medicine.
“They specifically have a direct impact on cancer diagnosis and prognosis and also guide treatment decisions in this era of personalized medicine,” Prof. Hara Prasad Pati, honorary founder of the Hematology Research Foundation, who was a guest speaker at the CME, said.
Pointing out that these tests were outsourced from Odisha to other states by almost all hospitals and labs, speakers said that IMS and SUM Hospital was the first medical college and hospital in the state to have developed in-house NGS facility.
The molecular and genomics tests were complicated high-end tests which required not only advanced laboratory set up but also special technical and reporting expertise. The advent of genomics era in the state would highly benefit patient care and research, they said.
IMS and SUM Hospital, being part of a Deemed to be University and a Medical College, was making good academic progress which would benefit the people at large, Prof. (Dr.) Pati said adding “this CME is proof of the academic excellence the institution has achieved.”
Prof. (Dr.) Pushparaj Samantasinhar, Medical Superintendent of IMS and SUM Hospital, said the institute had been setting new bench marks in the field of health care and had recently become the first to employ the Chimeric Antigen Receptor-T cell (CAR T-cell) therapy to treat a young blood cancer patient successfully. It had already conducted more than 70 Bone Marrow Transplantations (BMT) with success, he said.
Dr. Priyanka Samal, Head of Clinical Hematology, said that her department had received the support of all other departments in undertaking the CAR T-cell treatment of the patient. “Every day is a day of learning while the patient load is on the rise,” she said.
Dr. Shivangi Harankhedkar, Head of the hospital’s Molecular and Genomics Lab, was the Organizing Secretary of the event.
Prof. (Dr.) Rajashree Panigrahy, Laboratory Director, Prof. (Dr.) Soumya Surath Panda, Head of Medical Oncology, Prof. (Dr.) Debahuti Mahapatra, Head of Pathology, Prof. (Dr.) Rajesh Kumar Bhola, Head of Lab Hematology and faculties of different departments took part in the proceedings.
